Aim: Papillary renal cell carcinoma type 1 (pRCC1) represents the second most common type of malignant renal epithelial tumour. The origin of its characteristic appearance, its growth mechanism, and the long-term efficiency of its surgical treatment remain uncertain. Our aim was to determine typical characteristics of surgically treated pRCC1. Methods: pRCC1 was verified in 83 of 1,629 (5.1%) kidney tumours surgically treated in the period of January 2007-January 2016. The clinical and radiological characteristics, type of surgery, histopathology results and follow up data were recorded. Spearman correlation, Kruskal-Wallis analysis of variance, Fisher's exact, and chi-square test were used to analyse appropriate variables. The overall survival rate was evaluated using the Gehan-Wilcoxon test and the Cox proportional hazards model. Results: The mean tumour size was 52.0 mm (15-180); 98.8% of the tumours showed a spherical shape and in 82.1%, exophytic growth was observed. Partial nephrectomy was performed in 80.7%. A majority (81.9%) were classified as pT1. Tumours, 89.2% of them, belonged to Fuhrman grade 1 or 2. The mean follow-up was 46.8 months. The overall survival was associated with pT category (p ≤ 0.0001). Conclusions: Typical signs of pRCC1 are a spherical shape, exophytic growth and low Fuhrman's grade. More than three-fourths of pRCC1 could be treated by the nephron-sparing surgery.

Keywords:
Papillary, Classification, Prognosis, Stage, Grade
1.
Moch H, Humphrey PH, Ulbright TM, Reuter VE (eds): WHO Classification of Tumours of the Urinary System and Male Genital Organs, ed 4. Lyon, IARC, 2016, p 356.
2.
Epidemiology of malignant tumors in the Czech Republic (2015): Publishing Official Portal of the Czech National Cancer Control Programme. http://www.svod.cz/?sec=aktuality&lang=en (accessed March 8, 2016).
3.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924.
4.
Amin MB, Amin MB, Tamboli P, Javidan J, Stricker H, de-Peralta Venturina M, et al: Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 2002;26:281-291.
5.
Hora M, Hes O, Reischig T, Ürge T, Klečka J, Ferda J, et al: Tumours in end-stage kidney. Transplant Proc 2008;40:3354-3358.
6.
Woldu S, Weinberg AC, RoyChoudhury A, Chase H, Kalloo SD, McKiernan JM, et al: Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int Urol Nephrol 2014;46:2127-2132.
7.
Bard RH, Lord B, Fromowitz F: Papillary adenocarcinoma of kidney. II. Radiographic and biologic characteristics. Urology 1982;19:16-20.
8.
Weibl P, Hora M, Kollarik B, Shariat SF, Klatte T: Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. World J Urol 2015;33:295-300.
9.
Hora M, Hes O, Boudova L, Chudacek Z, Ouda Z, Michal M, et al: Papilarni renalni karcinom. Czech Urol 2002;6:26-31.
10.
Delahunt B, Eble JN: Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537-544.
11.
Ürge T, Hes O, Ferda J, Chudáček Z, Eret V, Michal M, et al: Typical signs of oncocytic papillary renal cell carcinoma in everyday clinical praxis. World J Urol 2010;28:513-517.
12.
Kutikov A, Uzzo RG: The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009;182:844-853.
13.
Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A, et al; Members of the ISUP Renal Tumor Panel: Handling and staging of renal cell carcinoma: the international society of urological pathology consensus (ISUP) conference recommendations. Am J Surg Pathol 2013;37:1505-1517.
14.
Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-663.
15.
Agresti A, Coull BA: Approximate is better than ‘exact' for interval estimation of binomial proportion. Am Stat 1998;52:119-126.
16.
Mileto A, Marin D, Alfaro-Cordoba M, Ramirez-Giraldo JC, Eusemann CD, Scribano E, et al: Iodine quantification to distinguish clear cell from papillary renal cell carcinoma at dual-energy multidetector CT: a multireader diagnostic performance study. Radiology 2014;273:813-820.
17.
Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, et al: Utility and limitations of 3-tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. Eur J Radiol 2014;83:909-913.
18.
Hora M, Hes O, Klecka J, Boudová L, Chudácek Z, Kreuzberg B, et al: Rupture of papillary renal cell carcinoma. Scand J Urol Nephrol 2004;38:481-484.
19.
Remzi M, Özsoy M, Klingler HC, Susani M, Waldert M, Seitz C, et al: Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol 2006;176:896-899.
20.
Tsui KH, Shvarts O, Smith Rb, Figlin R, De Kernion Jb, Belldegrun A: Renal cell carcinoma: prognostic significance of incidentally detected tumors. J Urol 2000;163:426-430.
21.
Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763-2771.
22.
Kim SH, Yang HK, Moon KC, Lee ES: Localized non-conventional renal cell carcinoma: prediction of clinical outcome according to histology. Int J Urol 2014;21:359-364.
23.
Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, et al: The epidemiology of renal cell carcinoma. Eur Urol 2011;60:615-621.
24.
Dong D, Ji Z, Li H, Yan W, Zhang Y: Laparoscopic nephron sparing surgery assisted with laparoscopic ultrasonography on centrally located renal tumor - single center experience. Urol Int 2016, Epub ahead of print.
25.
Bahouth Z, Halachmi S, Masarwa I, Avitan O, Nativ O: Nephron sparing surgery for renal mass: is there any difference between oncocytoma and malignant lesions. Urol Int 2016, Epub ahead of print.
26.
Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM: Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol 2001;32:590-595.
27.
Pignot G, Elie C, Conquy S, Vieillefond A, Flam T, Zerbib M, et al: Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification. Urology 2007;69:230-235.
28.
Yamanaka K, Miyake H, Hara I, Inoue TA, Hanioka K, Fujisawa M: Papillary renal cell carcinoma: a clinicopathological study of 35 cases. Int J Urol 2006;13:1049-1052.
29.
Méjean A, Hopirtean V, Bazin JP, Larousserie F, Benoit H, Chrétien Y, et al: Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality. J Urol 2003;170:764-767.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.